Neurocrine to begin Phase IIb of tardive dyskinesia drug despite 'inconsistencies'
This article was originally published in Scrip
Executive Summary
Neurocrine Biosciences has announced that even though there were "data inconsistencies" at one study site, a Phase II trial investigating its VMAT2 Inhibitor NBI-98854 for the treatment of tardive dyskinesia has provided it "with the necessary information and confidence to move forward into the larger Phase IIb trials as planned".